Follicular Lymphoma

Follicular lymphoma is one of the most common kinds of non-Hodgkin lymphoma. Its progression rate varies widely, though it tends to spread slowly and has few symptoms. Patients with follicular lymphoma usually survive ten years or longer.
What is Follicular Lymphoma?

Follicular lymphoma is a cancer of the B-cells that accounts for around one third of all cases of lymphoma. The cancer is a form of non-Hodgkin lymphoma that usually affects adults, with an average age-at-diagnosis of 60. Follicular lymphoma is more common among women than among men.

Read More

Overview

Feature Articles

Latest Follicular Lymphoma News and Research

Yale and AI Therapeutics launch clinical trial of potential COVID-19 drug

Yale and AI Therapeutics launch clinical trial of potential COVID-19 drug

Combining two immunotherapies into a single treatment found to be more effective

Combining two immunotherapies into a single treatment found to be more effective

Study shows potential new approach to treating two common subtypes of lymphoma

Study shows potential new approach to treating two common subtypes of lymphoma

Next-generation sequencing can detect genetic alterations specific to follicular lymphoma

Next-generation sequencing can detect genetic alterations specific to follicular lymphoma

Experimental immunotherapy can put patients with relapsed or refractory lymphoma into remission

Experimental immunotherapy can put patients with relapsed or refractory lymphoma into remission

Cancer patients share survivorship story, celebrate strength and self-care

Cancer patients share survivorship story, celebrate strength and self-care

HCA Healthcare UK introduces ground-breaking new blood cancer treatment

HCA Healthcare UK introduces ground-breaking new blood cancer treatment

T-cells play key role in how the body fights follicular lymphoma

T-cells play key role in how the body fights follicular lymphoma

CAR T therapy can lead to long-lasting remissions in patients with r/r diffuse large B-cell lymphoma

CAR T therapy can lead to long-lasting remissions in patients with r/r diffuse large B-cell lymphoma

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Phase 2 results on tazemetostat EZH2 inhibitor to be presented at ESMO 2018

Phase 2 results on tazemetostat EZH2 inhibitor to be presented at ESMO 2018

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

Verastem Oncology selects US Bioservices to dispense COPIKTRA capsules

Verastem Oncology selects US Bioservices to dispense COPIKTRA capsules

FDA lifts partial clinical hold that paused enrollment of new patients in tazemetosta clinical trials

FDA lifts partial clinical hold that paused enrollment of new patients in tazemetosta clinical trials

Verastem doses first patient in Phase I/II clinical trial of duvelisib in combination with venetoclax

Verastem doses first patient in Phase I/II clinical trial of duvelisib in combination with venetoclax

Celgene to share new and updated data around novel hematological therapies

Celgene to share new and updated data around novel hematological therapies

New compounds targeting epigenetics show promise in lymphoma patients

New compounds targeting epigenetics show promise in lymphoma patients

Study reveals HCT as effective treatment for NHL patients regardless of age

Study reveals HCT as effective treatment for NHL patients regardless of age

CAR T cell therapy shows long-lasting remissions in non-Hodgkin's lymphoma patients

CAR T cell therapy shows long-lasting remissions in non-Hodgkin's lymphoma patients

VICC selected to administer FDA-approved CAR T therapy for treatment of lymphoma patients

VICC selected to administer FDA-approved CAR T therapy for treatment of lymphoma patients